What: Having risen only 9.6% since its launch – unusual for a 2013 IPO – Lifehealthcare Group Ltd‘s (ASX: LHC) results today show there might be something to get excited about.
Better market penetration and a wider range of products on offer also look likely to generate further growth in the future once the usual costs associated with an IPO are left behind.
- Sales revenue rose 13.4% to $87.2 million
- Underlying EBITDA rose 8% to $15.3 million
- Net Profit After Tax rose 7.5% to $7.2 million
- Net debt down to $20.3 million (from $24 million at 30 June last year)
- Final dividend of 7.5 cents per share
- Targeting further market expansion in three main channels; Spine/Neurosurgery, Orthopaedics, and Cardiology
- 12-month hedging program and 7-month inventory stocks allow significant protection from currency risks
According to management, profit growth lagged revenue as a result of increased sales of low-margin ‘capital equipment’ and introductory price offers for new products that have now returned to normal levels.
Lifehealthcare’s strategy going forwards will be to further advertise its presence in the market and use its highly trained sales staff to generate sales to key specialists in each of the three channels.
Ideally initial sales will lead to follow-up orders in the future, and much of this depends on the quality of Lifehealthcare’s product, its sales staff, and its supply chain.
Investors should bear in mind that Lifehealthcare is essentially a sales company, and management admits that its future success depends ‘to a significant extent on the performance and expertise of key staff’ and the ability to retain them.
Efficient administration, ordering systems and customer support will help both with staff and customer retention and a continued focus on these factors will be valuable, particularly as total sales grow.
The annual report was short on details regarding future developments and results, noting that the company was presently focussed on consolidating its operations to ensure an effective operating model.
This is normal following an IPO, and management does note that it expects a reasonable year-on-year increase in its results for FY2015.
With an unhealthy, ageing population, Australian demand for medical services is expected to grow significantly over the next decade or more, and Lifehealthcare investors should enjoy steadily rising sales even before the company’s plans for expansion.
With its current modest valuation – not even 10% above its IPO price – Lifehealthcare represents a value purchase for the long-term shareholder.
Investors looking for a company with long-term tailwinds and the potential for strong, reliable earnings increases should also take a look at The Motley Fool‘s free report on our latest Top Stock recommendation.
Trading on a similar valuation to Lifehealthcare, this small company enjoys even more rapid growth without the handicaps of post-IPO expenses and consolidation.
If this sounds like the kind of share you’re looking for, simply click on the link below and enter your email address – it takes less than 30 seconds – and we’ll send it to you, completely FREE!
We hear it over and over from investors, "I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I'd be sitting on a gold mine!" And it's true.
And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!
*Extreme Opportunities returns as of June 5th 2020
Motley Fool contributor Sean O'Neill owns shares in Lifehealthcare.
- Results: Is G8 Education Ltd a buy for its 4% dividend? – August 27, 2018 12:22pm
- Results: Why the Adacel Technologies Limited (ASX:ADA) share price is down 7% – August 26, 2018 9:54pm
- Results: Why the Nearmap Ltd (ASX:NEA) share price is up 4% today – August 22, 2018 5:15pm